To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Yomiuri Shimbun file photo The Health, Labor and Welfare Ministry
The Yomiuri Shimbun
18:13 JST, September 25, 2023
The Health, Labor and Welfare Ministry on Monday approved the domestic manufacture and sale of Lecanemab, a new drug for the treatment of Alzheimer’s disease.
Lecanemab was jointly developed by Eisai Co. of Japan and Biogen Inc. of the United States. The drug is expected to be covered by health insurance within this year and become available for treatment.
It is the first drug proven to be effective in slowing the progression of Alzheimer’s by removing a substance believed to cause the disease.
